Pfizer Sees 5% Growth In Second Half; Currency, Competition Hurt Sales

Pfizer's revised forecast for 2004 revenues indicates that the company expects sales growth of about 5% during the second half of the year

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet